Search results

Skip to results

Type

Status

Last updated

Showing 1 to 2 of 2 results for naltrexone with bupropion

  1. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Published
    12 December 2017
    View recommendations

    Sections for TA494

  2. Past appeals and decisions

    therapy) 30 September 2016 TA494 Obesity (prolonged-release) - naltrexone-bupropion 12 December 2017 ID3913 Olipudase alfa...